BIO-TECHNE Corp Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
BIO-TECHNE Corp (TECH) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 0.50% for the 3-month period ending 2012-09-30, per its 10-Q filed 2012-11-09.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2012-11-09
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2012-09-30 was 0.50%, a 64.29% decline year-over-year.
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2011-12-31 was 1.90%, a 5.00% decline year-over-year.
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2011-09-30 was 1.40%, a 0.00% change year-over-year.
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2010-12-31 was 2.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month |
|---|---|
| 2012-09-30 | 0.50% 10-Q · filed 2012-11-09 |
| 2011-12-31 | 1.90% 10-Q · filed 2012-02-07 |
| 2011-09-30 | 1.40% 10-Q · filed 2012-11-09 |
| 2010-12-31 | 2.00% 10-Q · filed 2012-02-07 |
| 2010-09-30 | 1.40% 10-Q · filed 2011-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |